To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
125
Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Hydroxychloroquine administered as a loading dose only
Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
Expo Covid Center
Lahore, Punjab Province, Pakistan
Mayo Hospital
Lahore, Punjab Province, Pakistan
Pakistan Kidney and Liver Institute
Lahore, Punjab Province, Pakistan
RT-PCR negative status
Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Time frame: 6-7 days
Progression of symptoms
Time to progression to next stage of SARS-CoV-2 disease severity index
Time frame: 7 days
Development of Symptoms
Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate \>22 per minute).
Time frame: 7 days
Adverse events
Drug related adverse events as determined by data safety and monitoring board (DSMB)
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Standard of Care plus placebo